Drug	Target	Antibody type	FDA-approved indications	Toxicities, side effects, and precautions	Monitoring
Alemtuzumab (Campath)	CD52	Humanized, unconjugated	Chronic lymphocytic leukemia	Hematologic toxicity; opportunistic infections; rash	CBC; CD4 counts
				Live vaccines should be avoided
				Herpes and Pneumocystis prophylaxis recommended
Bevacizumab (Avastin)	VEGF	Humanized, unconjugated	Colorectal cancer, non-small cell lung cancer (nonsquamous)	Gastrointestinal perforation; wound healing complications; hemorrhage; arterial and venous thromboembolism; proteinuria; hypertension	Urinalysis; blood pressure
				Discontinue use several weeks before elective surgery; do not restart until surgical incision has healed
Cetuximab (Erbitux)	EGFR	Chimeric, unconjugated	Colorectal cancer, head and neck cancers	Acneiform rash; diarrhea; hypomagnesemia; nausea and vomiting; interstitial lung disease (rare)	Electrolyte levels; signs of inflammatory and infectious sequelae in patients with dermatologic toxicity; signs of pulmonary toxicity
Gemtuzumab Ozogamicin (Mylotarg)	CD33	Humanized, toxin conjugate (calicheamicin)	Acute myeloid leukemia	Severe myelosuppression; hepatotoxicity	CBC; electrolyte levels; liver chemistries
90Y-Ibritumomab Tiuxetan (Zevalin)	CD20	Murine, radioisotope conjugate (yttrium-90)	Non-Hodgkin's lymphoma	Severe, prolonged myelosuppression; severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome); risk of secondary malignancies (e.g., acute myeloid leukemia)	CBC; pretreatment antibody titers in patients who have received other murine-based radioimmunotherapy regimens
				Radiation safety precautions required for one week after administration*
Panitumumab (Vectibix)	EGFR	Human, unconjugated	Colorectal cancer	Acneiform rash; diarrhea; hypomagnesemia; hypocalcemia; nausea and vomiting; interstitial lung disease (rare)	Electrolyte levels; signs of inflammatory and infectious sequelae in patients with dermatologic toxicity; signs of ocular toxicity (e.g., conjunctivitis, ocular hyperemia, increased lacrimation, eye or eyelid irritation)
Rituximab (Rituxan)	CD20	Chimeric, unconjugated	Non-Hodgkin's lymphoma, rheumatoid arthritis	Lymphocytopenia; HBV reactivation; severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome)	CBC; signs of active HBV infection or hepatitis in patients who are HBV carriers
				Live vaccines should be avoided
131I-Tositumomab (Bexxar)	CD20	Murine, radioisotope conjugate (iodine-131)	Non-Hodgkin's lymphoma	Hypothyroidism; severe, prolonged myelosuppression; nausea and vomiting; secondary malignancies (e.g., acute myeloid leukemia)	CBC; thyroid function tests; pretreatment antibody titers in patients who have received other murine-based radioimmunotherapy regimens
				Radiation safety precautions required for one week after administration*
Trastuzumab (Herceptin)	HER2/neu	Humanized, unconjugated	Breast cancer with HER2/neu overexpression	Cardiomyopathy (especially if coadministered with anthracycline chemotherapy); cytopenias; rash	Electrocardiography; left ventricular ejection fraction